Latest news

Thumbnail image for Pfizer files lung cancer drug in the EU, US

Pfizer files lung cancer drug in the EU, US

Pfizer has filed its pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib on both sides of the Atlantic for a particular form of lung cancer.

5th April 2018

Thumbnail image for EU green light for Chiesi’s Lamzede

EU green light for Chiesi’s Lamzede

European regulators have green-lighted Chiesi’s Lamzede as the first long-term enzyme replacement therapy to treat non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.

5th April 2018

Thumbnail image for BI snaps up OSE’s novel checkpoint inhibitor

BI snaps up OSE’s novel checkpoint inhibitor

Boehringer Ingelheim and OSE Immunotherapeutics have joined forced to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells for the treatment of advanced solid tumours.

5th April 2018

Thumbnail image for EU expands scope of Amgen’s Xgeva

EU expands scope of Amgen’s Xgeva

European regulators have expanded the treatment scope of Amgen’s Xgeva to include the prevention of skeletal-related events in adults with multiple myeloma.

4th April 2018

Thumbnail image for EU reviews first PARP inhibitor for breast cancer

EU reviews first PARP inhibitor for breast cancer

MSD and AstraZeneca’s Lynparza will be the first PARP inhibitor to be reviewed in Europe for the treatment of breast cancer, after the European Medicines Agency validated the drug’s marketing application in this setting.

4th April 2018

Previous  --   1 2 3 4 5 6 7 8 9 10   --  Next

Latest jobs

View all

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download